

1. von Eckardstein A, Funke H, **Walter M**, Altland K, Benninghoven K, Assmann G. Structural analysis of apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. *J Biol Chem* 1990;265:8610-8617.
2. von Eckardstein A, **Walter M**, Benninghoven A, Assmann G. Site specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity in apolipoproteins A-I, C-II, and C-III. *J Lipid Res* 1991;32:1465-1476.
3. **Walter M**, Kerber S, Fechrup C, Seedorf U, Breithardt G, Assmann G. Characterization of atherosclerosis in a patient with familial high density lipoprotein deficiency (Tangier disease). *Atherosclerosis* 1994;110:203-208.
4. **Walter M**, Gerdes U, Seedorf U, Assmann G. The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. *Biochem Biophys Res Commun* 1994;205:850-856.
5. Seedorf U, **Walter M**, Assmann G. Diagnosis of Smith-Lemli-Opitz-syndrome. [Letter] *N Engl J Med* 1994;330:1685-1687.
6. Berendes E, **Walter M**, Prien T, Assmann G, Lawin P. Digoxin-like immunoreactive substance in critically ill patients. [Letter] *Anesthesiology* 1994;80:1408-1409.
7. **Walter M**, Kerber S, Fechrup C, Seedorf U, Breithardt G, Assmann G. Koronarangiographie und intravasculäre Ultraschalluntersuchung bei einem 60-jährigen Patienten mit familiärer HDL-Defizienz (Tangier-Krankheit). *Zf Kardiologie* 1994;83:381-385.
8. Tepel M, Heidenreich S, Zhiming Z, **Walter M**, Nofer J-R, Zidek W. Captopril inhibits the agonist-induced increase of cytosolic Ca^{2+} in glomerular mesangial cells. *Kidney Internat* 1994;46:696-702.
9. **Walter M**, Reinecke H, Nofer J-R, Seedorf U, Assmann G. HDL₃ stimulates multiple signaling pathways in human skin fibroblasts. *Arterioscler Thromb Vasc Biol* 1995;15:1975-1986.
10. Nofer J-R, ***Walter M**, Kehrel B, Seedorf U, Assmann U. HDL₃ activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. *Biochem Biophys Res Commun*. 1995;207:148-154.
11. Tepel M, Schlotmann R, Barenbrock M, Kisters K, Torsten K, Spieker C, **Walter M**, Meyer C, Bretzel RG, Zidek W. Lymphocytic Na^+-H^+ exchange increases after an oral glucose challenge. *Circ Res* 1995;77:1024-1029.
12. **Walter M**, Reinecke H, Gerdes U, Nofer J-R, Höbbel G, Seedorf U, Assmann G. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. *J Clin Invest*. 1996;98:2315-2323.
13. Wronska-Nofer T, Laurman W, Nofer J-R, Seedorf U, **Walter M**. Carbon disulfide-induced modification and cytotoxicity of low-density lipoproteins. *Toxicol in Vitro* 1996;10:423-429
14. Tepel M, Heidenreich S, Schlüter H, Beinlich A, Nofer J-R, **Walter M**, Assmann G, Zidek W. Diadenosine polyphosphates induce transplasma membrane calcium influx in cultured glomerular mesangial cells. *Eur J Clin Invest* 1996;26:1077-1084.
15. Nofer J-R, Tepel M, Kehrel B, **Walter M**, Seedorf U, Assmann G, Zidek W. High density lipoproteins enhance the Na^+/H^+ antiport in human platelets. *Thromb Haemost* 1996;75:635-641.
16. Nofer J-R, Tepel M, Kehrel B, **Walter M**, Seedorf U, Assmann G, Zidek W. Low density lipoproteins inhibit the Na^+/H^+ antiport in human platelets: a novel mechanism enhancing platelet activity in hypercholesterolemia. *Circulation* 1997;95:1370-1377.
17. Berendes E, ***Walter M**, Cullen P, Prien H, Schulte M, Horsthemke J, van Aken H, von Wild H, Scherer H. Brain natriuretic peptide secretion in patients with aneurysmal subarachnoid haemorrhage. *Lancet* 1997;349:245-249.
18. Berendes E, **Walter M**, Van Aken H, Berendes L, Assmann G, Prien T. Incidence of endogenous ouabain and digitalis-like immunoreactive substances in critically ill patients. *Anesthesiology* 1997;87.

19. Nofer J-R, Tepel M, **Walter M**, Seedorf U, Assmann G, Zidek W. Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes. *J Biol Chem* 1997;272:32861-32868.
20. Nofer J-R, ***Walter M**, Tepel M, Seedorf U, Assmann G. HDL₃-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol-1,4,5-trisphosphate. *Arterioscler Thromb Vasc Biol* 1998; 18:861-869.
21. **Walter M**, Reinecke H, Heinrich J, Breithardt G, Assmann G. Factor V Leiden and thromboembolism. *Circulation* 1998;97:1426-1427.
22. von Eckardstein A, Chirazi A, Lüttmann S, **Walter M**, Kastelein JJP, Kuivenhoven JA, Geisel J, Réal J, Miccoli R, Nosedà G, Höbbel G, Assmann G. Plasmas and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. *J Lipid Res* 1998;39:987-998.
23. Rust S, **Walter M**, Funke H, et al. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. *Nature Genetics* 1998;20:96-98.
24. Berendes E, Erren M, van Aken H, Assmann G, **Walter M**. Systemic inflammation and digitalis-like immunoreactive substances in critically ill patients. *Anesthesiology* 1998; 89.
25. Nofer JR, Höbbel G, Junker R, Fobker M, Pawlus E, **Walter M**, Assmann G. HDL 3-induced phosphatidylinositol-specific phospholipase C (PI-PLC) activation: Involvement in cell proliferation but not cholesterol efflux. *Atherosclerosis* 1999; 144:5-5.
26. Assmann G, von Eckardstein A, Funke H, Cullen P, **Walter M**, Schulte H. The protective role of HDL in atherosclerosis. *Atherosclerosis*; 1999; 144:3-4.
27. Assmann G, von Eckardstein A, Nofer JR, **Walter M**. Role of HDL in reverse cholesterol transport. *Atherosclerosis* 1999; 146:223-3
28. **Walter M**, Berendes E, Claviez A, Suttorp M. Inappropriate secretion of natriuretic peptides in a patient with a cerebral tumor. *JAMA* 1999;282:27-28.
29. Nofer JR, Junker R, **Walter M**, Seedorf U, Assmann G, Zidek W, Tepel M. Phospholipase A2 is involved in thapsigargin-induced sodium influx in human lymphocytes. *Arch Biochem Biophys* 2000;374:213-221.
30. **Walter M**, Tepel M, Nau P, Nofer JR, Neusser M, Assmann G, Zidek W. Involvement of phospholipase D in capacitative calcium entry. *FEBS Lett* 2000;479:51-56.
31. Nofer JR, Fobker M, Hobbel G, Voss R, Wolinska I, Tepel M, Zidek W, Junker R, Seedorf U, von Eckardstein A, Assmann G, **Walter M**. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. *Biochemistry* 2000;39:15199-207.
32. Fobker M, Voss R, Reinecke H, Crone C, Assmann G, **Walter M**. Accumulation of cardiolipin and lysocardiolipin in fibroblasts from Tangier disease subjects. *FEBS Lett* 2001;500:157-162.
33. Nofer JR, Junker R, Pulawski E, Fobker M, Levkau B, von Eckardstein A, Seedorf U, Assmann G, **Walter M**. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. *Thromb Haemost* 2001;85:730-5.
34. Utech M, Hobbel G, Rust S, Reinecke H, Assmann G, **Walter M**. Accumulation of RhoA, RhoB, RhoG, and Rac1 in fibroblasts from Tangier disease subjects suggests a regulatory role of Rho family proteins in cholesterol efflux. *Biochem Biophys Res Commun* 2001;280:229-36.
35. Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, **Walter M**. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. *Anesth Analg* 2001;93:676-82.
36. Berger TM, Kistler W, Berendes E, Raufhake C, **Walter M**. Hyponatremia in a pediatric stroke patient: SIADH or Cerebral Salt Wasting ? *Crit.Care Med* 2002;30:792-5

37. Berendes E, Cullen P, Van Aken H, Zidek W, Erren M, Hubschen M, Weber T, Wirtz S, Tepel M, **Walter M**. Endogenous glycosides in critically ill patients. *Crit Care Med*. 2003;31:1331-7.
38. Berendes E, Schmidt C, van Aken H, Grosse Hartlage M, Wirtz S, Reinecke H, Rothenburger M, Scheld HH, Schlüter B, Brodner G, **Walter M**. Reversible cardiac sympathectomy by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting. A randomized trial. *Arch. Surgery* 2003;138:1283-1290.
39. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, **Walter M**, Breithardt G, Schaefer RM. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. *Eur Heart J*. 2003;24:2142-50.
40. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, **Walter M**, Breithardt G, Schaefer RM. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. *Eur Heart J*. 2003;24:2142-2159.
41. Berendes E, Schmidt C, van Aken H, Raufhake C, Grosse Hartlage M, Rothenburger M, Scheld HH, **Walter M**. Atrial and brain natriuretic peptide in cardiac surgical procedures. *Anesth Analg* 2004;98:11-19 .
42. Heidrich J, Wellmann J, Fobker M, Wichter T, **Walter M**, Breithardt G, Schaefer RM, Reinecke H. Hemoglobin-depending mortality in patients undergoing percutaneous coronary interventions. *Biometrical Journal* 2004;46:44-44.
43. **Walter M**, Forsyth NR, Wright W, Shay JW, Roth MG. The establishment of telomerase-immortalized Tangier disease cell lines indicates the existence of an apolipoprotein A-I-inducible but ABCA1-independent cholesterol efflux pathway. *J Biol Chem* 2004;279:20866-20873.
44. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang SH, Glorioso JC, **Walter M**, Roth MG, Lazo JS. The LXR ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. *J. Biol. Chem*. 2005;280:4079-88.
45. Nofer JR, **Walter M**, Assmann G. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence [Review]. *Expert Rev Cardiovasc Ther*. 2005; 3:1071-1086.
46. Rudack C, Langer C, Stoll W, Rust S, **Walter M**. Vascular risk factors in sudden hearing loss. *Thromb Haemost*. 2006;95:454-461.
47. Meyer A, Bunzemeier H, Hausberg M, **Walter M**, Roeder N, Breithardt G, Reinecke H. Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease. *Nephrol Dial Transplant*. 2008;23:1955-60.
48. **Walter M**. Interrelationships among HDL metabolism, aging, and atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2009; 29:1244-50.
49. Reunert J, Wentzell R, **Walter M**, Jakubiczka S, Zenker M, Brune T, Rust S, Marquardt T. Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn. *Eur J Hum Genet*. 2012;20:933-7.
50. Soufi M, Rust S, **Walter M**, Schaefer JR. A combined LDL receptor/LDL receptor adaptor protein 1 mutation as the cause for severe familial hypercholesterolemia. *Gene*. 2013;521:200-3.
51. Kannenberg F, Gorzelniak K, Jäger K, Fobker M, Rust S, Repa J, Roth M, Björkhem I, **Walter M**. Characterization of cholesterol homeostasis in telomerase-immortalized Tangier disease fibroblasts reveals marked phenotype variability. *J Biol Chem*. 2013;288:36936-47.
52. Weiss D, Neuner B, Gorzelniak K, Bremer A, Rudack C, **Walter M**. Platelet glycoproteins and fibrinogen in recovery from idiopathic sudden hearing loss. *PLoS One*. 2014;9:e86898.